A Pharmacy Chain Running Out of Road
Walgreens built its empire on corner lots and convenience – the idea that a pharmacy should be within a few minutes of wherever you happen to be. For decades, that strategy worked. Now the chain is methodically dismantling it, closing stores at a pace that signals something deeper than a routine real estate adjustment. The closures are not a cost-cutting footnote. They are the most visible sign that the fundamental economics of retail pharmacy in America have stopped making sense.
The company has confirmed plans to shutter around 1,200 locations over the next three years, a number that would have seemed unthinkable a decade ago when Walgreens was still opening new stores and absorbing competitors.
What makes this moment different from past rounds of retail consolidation is that Walgreens is not closing stores because foot traffic moved to a competitor down the street. The customers are still there – they simply are not generating enough margin for a physical pharmacy to survive on them.
The Margin Problem That Prescription Fills Cannot Solve
The core tension inside any retail pharmacy is that prescriptions drive traffic but not necessarily profit. Pharmacy benefit managers – the intermediaries who negotiate drug prices between manufacturers, insurers, and pharmacies – have systematically compressed what pharmacies actually receive per prescription filled. For years, Walgreens and its peers absorbed those cuts by relying on front-of-store retail sales, where margins on shampoo, greeting cards, and energy drinks are far better than on a generic blood pressure medication. That cross-subsidy model is breaking down because front-end retail is losing ground to e-commerce and dollar stores simultaneously.
The result is a store that fills hundreds of prescriptions a day and still cannot cover its rent, labor, and operating costs. Labor is a particular pressure point. Pharmacy staff shortages have pushed wages up sharply, and the workload per pharmacist has intensified as vaccination services and medication counseling expanded. Several pharmacy chains, including Walgreens, faced very public staffing walkouts in recent years, with pharmacists citing unsustainable conditions. Closing the least-profitable stores is partly a response to that crisis – fewer locations, the logic goes, means better-staffed ones.
But that logic has a ceiling. Walgreens still needs to serve the customers in the markets it exits, and those customers do not disappear. Some will migrate to CVS or Rite Aid – though Rite Aid itself entered bankruptcy and is closing its own stores. Others will shift to mail-order pharmacy services or grocery store pharmacies, accelerating the very trends that made the standalone pharmacy model harder to sustain in the first place.
Private Equity, Debt, and the Sycamore Factor
Walgreens’ troubles are compounded by the fact that the company was already carrying significant debt and had made a series of expensive bets – most notably its investment in VillageMD, a primary care clinic chain it embedded in hundreds of Walgreens locations. The idea was straightforward: turn a pharmacy visit into a full healthcare appointment, increase customer stickiness, and capture more of the healthcare dollar. The execution has been expensive and slower to generate returns than anticipated. Walgreens has since pulled back, closing dozens of VillageMD clinics and writing down the investment.
In early 2025, private equity firm Sycamore Partners reached a deal to take Walgreens private in a transaction valued at roughly $10 billion. That figure, adjusted for debt, represented a fraction of what Walgreens was worth at its peak. Taking the company private removes the pressure of quarterly earnings scrutiny, but it also introduces the playbook that private equity typically applies to struggling retail: aggressive cost reduction, possible asset sales, and a compressed timeline to either stabilize or flip the business.
The store closure acceleration almost certainly fits within that playbook. Pruning underperforming locations quickly improves operating margins on paper and makes the remaining portfolio look healthier to future investors. Whether that restructuring actually fixes the underlying margin compression from pharmacy benefit managers is a separate question – and a harder one to answer by simply locking the doors on 1,200 stores.
What Closes When a Pharmacy Closes
The human cost of these closures tends to get lost in the financial mechanics. Walgreens, like CVS and Rite Aid, built its density in part by locating stores in communities that lacked strong grocery or healthcare infrastructure. When a Walgreens closes in a lower-income urban neighborhood or a rural county seat, it does not just remove a place to pick up a prescription – it often removes the nearest point of access for over-the-counter medications, blood pressure cuffs, wound care supplies, and basic health screenings. Pharmacy deserts are already a documented problem in the United States, and the current wave of closures is making the map worse.
There is also the question of what happens to the pharmacists and pharmacy technicians employed at closed locations. Walgreens has said it intends to retain employees where possible by offering transfers, but transfers require geographic flexibility that not every worker has. For staff who cannot relocate, a Walgreens closure can mean navigating a pharmacy job market that is simultaneously short-staffed systemically and shedding positions location by location.
Sycamore Partners now holds the controls on a chain that still operates thousands of locations, still fills millions of prescriptions annually, and still occupies some of the most valuable corner real estate in American cities – real estate that, in some markets, may ultimately be worth more as something else entirely. The closure plan answers the question of which stores cannot survive. It does not yet answer what Walgreens is supposed to become.
